Select a month January 2004 December 2003 November 2003" October 2003 September 2003 July 2003 June 2003 May 2003 April 2003 March 2003 February 2003 January 2003 December 2002 November 2002 October 2002 September 2002 August 2002 July 2002 June 2002 May 2002 April 2002 March 2002 February 2002 January 2002 December 2001 November 2001 October 2001

Studies in Humans: Reviews (Definition) Jump to: 2003: January  |  February  |  March  |  April  |   May  |   June  |   July  |   2002: January  |  February  |  March  |  April  |  May  |  June  |  July  |  August  |  September  |  October  |  November  |  December   2001: October  |  November  |  December July 2003 Butcher J. (2002) MDMA research leaves ravers far from ecstatic. Lancet Neurol 1 :398. June 2003 Verbaten MN (2003) Specific memory deficits in ecstasy users? The results of a meta- analysis. Hum Psychopharmacol 18: 281-290. May 2003 Lyles J, Cadet JL (2003) Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Rev 42: 155-168. Romanelli F, Smith KM, Pomeroy C (2003) Use of Club Drugs by HIV-Seropositive and HIV-Seronegative Gay and Bisexual Men. Top HIV Med 11: 25-32. April 2003 Cole JC, Sumnall HR (2003) Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98: 35-58. Lingford-Hughes A, Nutt D (2003) Neurobiology of addiction and implications for treatment. Br J Psychiatry 182: 97-100. Walters ST, Foy BD, Castro RJ (2003) The agony of ecstasy: responding to growing MDMA use among college students. J Am Coll Health 51: 139-41. March 2003 No updates available for March 2003 February 2003 No updates available for February 2003 January 2003 No updates available for January 2003 December 2002 No updates available for December 2002 November 2002 Bellis MA, Hughes K, Lowey H (2002) Healthy nightclubs and recreational substance use; from a harm minimization to a healthy settings approach. Addictive Behaviors 27, 1025-1035. October 2002 Antoniou T, Tseng AL (2002) Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 36: 1598-1613 September 2002 Cole, J, Sumnall H, Grob C (2002). Sorted: Ecstasy facts and fiction. The Psychologist, 15: 464-467. Cole J, Sumnall H, Grob C (2002). Where are the casualties? The Psychologist, 15: 474. Croft R (2002). "Danger" remains best message. The Psychologist, 15: 470-471. Freese TE, Miotto K, Reback CJ (2002). The effects and consequences of selected club drugs. J Subst Abuse Treatment 23: 151-156. Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL (2002). The health effects of ecstasy: a literature review. Drug Alcohol Rev 21: 53-63. Morgan M (2002). Throwing the baby out with the bath water. The Psychologist, 15: 468-469. Parrott A (2002). Very real, very damaging. The Psychologist, 15: 472-473. Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M (2002). Acute psychological and neurophysiological Effects of MDMA in humans. J Psychoactive Drugs, 34: 171-184. August 2002 Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M (2002) Action of MDMA (Ecstasy) and Its Metabolites on Arginine Vasopressin Release. Ann N Y Acad Sci 965: 399-409. McKenna C (2002) Ecstasy is low in league table of major causes of deaths. Bmj 325: 296. Montoya AG, Sorrentino R, Lukas SE, Price BH (2002) Long-Term Neuropsychiatric Consequences of "Ecstasy" (MDMA): A Review. Harv Rev Psychiatry 10: 212-220. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuno J, Menoyo E, Segura J, de la Torre R (2002) Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965: 421-433. Rothman R, Baumann M (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95: 73-88 July 2002 Smith KM, Larive LL, Romanelli F (2002) Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 59: 1067-1076. June 2002 Anonymous (2002). Ecstasy. Psychiatric Services 53(6): 667 May 2002 Hess D, DeBoer S (2002). Ecstasy: This designer drug is increasing in popularity and may be coming soon to an ED near you. Am J Nurs 102: 45-47 Hurley RA, Reneman L, Taber KH (2002). Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatry Clin Neurosci 14: 125-129 Koesters SC, Rogers PD, Rajasingham CR (2002). MDMA ('ecstasy') and other 'club drugs'. The new epidemic. Pediatr Clin North Am 49: 415-433 April 2002 Kraemer T, Maurer HH (2002). Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24: 277-289 March 2002 Kish SJ (2002). How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacology, Biochemistry and Behavior, 71(4), 845-8551 Parrott AC (2002). Recreational ecstasy/MDMA: The serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav, 71: 837-844 February 2002 Teter CJ, Guthrie, SK (2001). A comprehensive review of MDMA and GHB; Two common club drugs. Pharmacotherapy, 21(12): 1486-1513 January 2002 Liechti ME, Vollenweider FX (2001). Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Human Psychopharmacology, 16: 589-598 O'Leary G, Nargiso J, Weiss RD (2001). 3,4-methylenedioxymethamphetamine (MDMA): A Review. Curr Psychiatry Rep 3: 477-483 Parrott AC, Milani RM, Parmar R, Turner JD (2001). Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology (Berl) 159: 77-82 Pentney AR (2001). An exploration of the history and controversies surrounding MDMA and MDA. J Psychoactive Drugs 33: 213-221 Pham JV, Puzantian T (2001). Ecstasy: Dangers and Controversies. Pharmacotherapy 21: 1561-1565 Vickrey V (2001). Like Russian roulette, ecstasy is a game of life or death. Mich Med 100: 53 Wood R, Synovitz LB (2001). Addressing the threats of MDMA (Ecstasy): implications for school health professionals, parents, and community members. J Sch Health 71: 38-41 December 2001 Doyon S (2001). The many faces of ecstasy. Curr Opin Pediatr 13: 170-6. November 2001 Kalant, H (2001). The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Canadian Medical Association Journal, 165: 917-92 October 2001 Braff, DL, Geyer, MA & Swerdlow, NR (2001). Human studies of prepulse inhibition of startle: normal subjects. Patient groups, and pharmacological studies. Psychopharmacology, 157: 234-258. Murray, JB (2001). Ecstasy is a dangerous drug. Psychological Reports, 88: 895-902.